Could Today's Breaking News Provide (TCBP) With A Breakout Spark? Currently Up Approx. 15%
TCBP is steaming hot right now.
On the heels of breaking news this morning, TCBP is currently up approximately 15%.
It even hit highs around $5.75 during pre-market.
Read the news yet? Here it is:
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings
EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.
"We are enthusiastic about working with MD Anderson to further our knowledge of gamma delta T cells in order to help TC Biopharm develop future trials and treatments using our platform therapy OmnImmune," said Bryan Kobel, CEO of TC BioPharm. "This collaboration reinforces our mutual commitment to accelerating the discovery and development of cell therapies, and it highlights TC Biopharm's expertise in the gamma delta T cell space."
Read the full article here.
Remember, this is a low float profile (under 1Mn shares). That means when the company releases positive news, the potential for volatility grows significantly.
Read my initial report below and get TCBP on your radar now.
We've got a minute, so let's chat.
My alert from this past Tuesday continued to move green all the way to Friday's closing bell.
Hitting a high of $5.03 Friday, it officially moved approximately 19% from its Tuesday open of $4.21.
Plus, when it hit a new 2-month high on Friday, we were able to crown another champ.
But that's not all...
January 4th's profile surged approximately 15% intraday.
December 30th's profile rocketed approximately 94% within a week.
December 28th's profile blasted approximately 20% in the span of 3 days.
See a pattern forming?
We've put together a strong run of breakout champs, but nothing may hold a torch to our next idea.
Based on a mind-blowing low float of fewer than 1Mn shares, an explosive chart history full of $1.00+ intraday blasts, and advancing testing of a lead drug candidate (dosed first three patients within Phase 2b clinical trial), this Nasdaq profile needs to be on your radar:
TC Biopharm (Holdings) Plc (Nasdaq: TCBP)
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia.
And based on these potential catalysts, TCBP could be a near term breakout candidate. Check them out:
No. 1 - A Wildly Low Float Could Create Environment For Daily Volatility
No. 2 - A Super Explosive Chart History (See What Happened Friday?)
No. 3 - Key Milestone Achieved Within Phase 2b Clinical Trial
No. 4 - Another Amazing Achievement For Company's Lead Product OmnImmune®
But more on those in a second...
The Leading Gamma-Delta T-Cell Company
Vertically integrated operations, along with building exceptional teams and capabilities, allows TC BioPharm to move quickly, providing unique ability to rapidly respond to internal discovery and external factors.